Stay updated on clinical development milestones and clinical trial approvals we are proud to help our sponsors achieve
If you were at the DIA Global Annual Meeting 2019 on June 23-27 in San Diego, you may have encountered the OCT delegation members on few occasions. DIA is more than just a traditional meeting, the event has been a landmark, must-attend gathering for more than 50 years. This year it became a meeting point for stakeholders from across the entire drug development spectrum, from discovery to marketed use, to facilitate open collaboration by incorporating representatives from the whole life sciences industry.
The hottest discussions took place within sessions on patient engagement, global pediatric studies, medical regulation updates, drug development tools, and risk-based monitoring solutions — a brief course with core concepts and key tools.
With recent advancements in technology, new techniques in medicine have been becoming more available. Speakers stated that the alliance of technology and science will definitely reshape the drug development process. The numerous sessions on artificial intelligence, including challenges in adapting and advanced approaches in leveraging real-time access to clinical data and analytics were held. A lot has been said about innovative emerging technologies to collect data from and about patients in clinical research (ePRO, BYOD, etc.).
"I came back from this conference with renewed energy. It is a great platform to learn, engage and generate insights on clinical trials. DIA provided me with the opportunity to meet a lot of interesting people with different backgrounds and knowledge", — commented Irina Petrova, Director of Clinical Operations in OCT.
* - Required fields